Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

June 18, 2024

https://www.globenewswire.com/news-release/2024/06/18/2900391/0/en/Day-One-Expands-Pipeline-with-Potential-First-in-Class-Clinical-Stage-Antibody-Drug-Conjugate-ADC-Targeting-PTK7-in-Solid-Tumors-for-Adult-and-Pediatric-Cancers.html

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024

Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.